Somewhat Favorable News Coverage Somewhat Unlikely to Impact Strongbridge Biopharma (SBBP) Share Price
Press coverage about Strongbridge Biopharma (NASDAQ:SBBP) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Strongbridge Biopharma earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.5515267700326 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Zacks: Brokerages Expect Strongbridge Biopharma plc (SBBP) to Announce -$0.31 EPS (americanbankingnews.com)
- Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome (finance.yahoo.com)
- Strongbridge Biopharma (SBBP) Rating Reiterated by HC Wainwright (americanbankingnews.com)
- Strongbridge Biopharma (SBBP) Cut to Hold at Zacks Investment Research (americanbankingnews.com)
- Cantor Fitzgerald Analysts Give Strongbridge Biopharma (SBBP) a $14.00 Price Target (americanbankingnews.com)
Strongbridge Biopharma (NASDAQ:SBBP) opened at $8.45 on Tuesday. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma has a 1 year low of $2.10 and a 1 year high of $8.85. The firm has a market cap of $336.41 and a P/E ratio of -2.50.
Several research firms recently weighed in on SBBP. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. BidaskClub upgraded shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Cantor Fitzgerald set a $14.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, ValuEngine cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $12.81.
About Strongbridge Biopharma
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.